Ignite Creation Date:
2024-05-06 @ 3:34 PM
Last Modification Date:
2024-10-26 @ 1:51 PM
Study NCT ID:
NCT04671355
Status:
WITHDRAWN
Last Update Posted:
2022-02-03
First Post:
2020-10-28
Brief Title:
TRIMBOW and RELVAR on Lung Stiffness Reduction Assessed Through Forced Oscillation Technique in Patients With COPD
Sponsor:
Chiesi Farmaceutici SpA
Organization:
Chiesi Farmaceutici SpA
Study Overview
Official Title:
A Phase IV Open Label Multicentre Randomised 2-way Cross-over Exploratory Clinical Trial Comparing TRIMBOW pMDI and RELVAR ELLIPTA DPI on Lung Stiffness Reduction Assessed Through Area Under the Reactance Curve AX in COPD
Status:
WITHDRAWN
Status Verified Date:
2022-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Continuing delays due to COVID-19 pandemic
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Efficacy of TRIMBOW pMDI and RELVAR ELLIPTA DPI on lung stiffness reduction assessed through area under the reactance curve AX using oscillometry in chronic obstructive pulmonary disease COPD
Detailed Description:
An open label multicentre randomised 2-way cross-over exploratory clinical trial comparing a fixed combination of beclometasone dipropionate plus formoterol fumarate plus glycopyrronium administered via pMDI TRIMBOW and a fixed combination of fluticasone furoate plus vilanterol administered via DPI RELVAR ELLIPTA on lung stiffness reduction assessed through area under the reactance curve AX using forced oscillation technique FOT in patients with chronic obstructive pulmonary disease COPD
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2019-002744-24 | EUDRACT_NUMBER | None | None |